Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2001

01-04-2001 | Conference Report

Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer

Authors: Gemma Dominguez, Jose M. Silva, Javier Silva, Jose M. Garcia, Antonio Sanchez, Antonia Navarro, Isabel Gallego, Mariano Provencio, Pilar España, Felix Bonilla

Published in: Breast Cancer Research and Treatment | Issue 3/2001

Login to get access
Metadata
Title
Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer
Authors
Gemma Dominguez
Jose M. Silva
Javier Silva
Jose M. Garcia
Antonio Sanchez
Antonia Navarro
Isabel Gallego
Mariano Provencio
Pilar España
Felix Bonilla
Publication date
01-04-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 3/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1010624717311

Other articles of this Issue 3/2001

Breast Cancer Research and Treatment 3/2001 Go to the issue

Other Index

Subject Index, Volume 66

Conference Report

Breast Cancer Survival and in Vitro Tumor Response in the Extreme Drug Resistance Assay

Conference Report

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

Conference Report

Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer

Conference Report

Sun Valley Summary

Conference Report

Association of NK Cell Dysfunction with Changes in LDH Characteristics of Peripheral Blood Lymphocytes (PBL) in Breast Cancer Patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits